NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) today announced the appointment of Warren W. Wasiewski, M.D., F.A.A.P. as its Vice President of Clinical Programs. Dr. Wasiewski will lead the clinical development program for Viprinex(TM) (ancrod), a reperfusion agent currently in Phase III development for acute ischemic stroke. Dr. Wasiewski, age 54, is a Board Certified Pediatric Neurologist with an extensive clinical career. He joins NTI from AstraZeneca LP, where he most recently was the Sr. Medical Director of Clinical Research CNS/Emerging Products. During his career at AstraZeneca, Dr. Wasiewski played a pivotal role in the execution and development of the company's Phase III clinical studies for acute ischemic stroke, known as the SAINT I and SAINT II trials. Paul E. Freiman, President and CEO, said, "The decision to hire Warren is another example of our commitment to the Viprinex Phase III program. His expertise in neurology, strong relationships with key opinion leaders in the stroke field and ability to direct complex stroke clinical trials further enhances our capabilities in executing studies of this magnitude." Dr. Wasiewski said, "I am happy to be part of the NTI team, and look forward to working with an experienced group of individuals. I believe that NTI has the potential to accomplish something desperately needed in the field of stroke with Viprinex and I'm looking forward to being able to contribute at this crucial stage of the program." Dr. Wasiewski's career includes 19 years in Pediatric Neurology. Prior to joining AstraZeneca, he was Chairman of Pediatrics at Lancaster General Hospital from 1998 to 2001 and from 1991 to 2001 he was a Consultant Neurologist at Pediatric Neurology Associates in Lancaster, Pennsylvania a practice he founded in 1991. Prior to founding Pediatric Neurology Associates he was an assistant professor of Pediatrics at Penn State Medical School in Hershey PA. Among his professional affiliations, Wasiewski is a Fellow of the American Academy of Neurology, Fellow of the American Academy of Pediatrics, a member of Alpha Omega Alpha the national Medical Honor Society and a member of the American Heart Association. He is widely published in areas of disease of the central nervous system including migraine and stroke. Dr. Wasiewski holds a Bachelor of Arts in Biology Cum Laude from Rutgers College, a Masters of Science in Biochemistry from State University of New York Downstate Medical Center, and a Doctorate of Medicine from State University of New York, at Buffalo. About Neurobiological Technologies, Inc. NTI is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. The Company is focused on therapies for neurological conditions that occur in connection with ischemic stroke and brain cancer. The Company's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our need for additional capital, risks relating to the regulatory approval and commercialization of Viprinex, the inherent risk of failure in developing product candidates based on new technologies, the risks associated changes in our management team and other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Paul E. Freiman, President and CEO of Neurobiological Technologies, Inc., +1-510-595-6000 Web site: http://www.ntii.com/

Copyright